Obalon Therapeutics (NASDAQ:OBLN) announced its earnings results on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.24), MarketWatch Earnings reports. Obalon Therapeutics had a negative return on equity of 115.36% and a negative net margin of 694.12%. The business had revenue of $0.70 million for the quarter.

Shares of NASDAQ:OBLN traded down $0.02 on Friday, reaching $0.68. 146,617 shares of the company’s stock were exchanged, compared to its average volume of 293,249. The company has a fifty day moving average of $0.77 and a 200-day moving average of $1.09. Obalon Therapeutics has a twelve month low of $0.62 and a twelve month high of $5.97. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.97 and a current ratio of 2.17.

About Obalon Therapeutics

Obalon Therapeutics, Inc, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc was founded in 2008 and is headquartered in Carlsbad, California.

Featured Article: Moving Average Convergence Divergence (MACD)

Earnings History for Obalon Therapeutics (NASDAQ:OBLN)

Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.